Narodny Endokrinologicky A Diabetologicky Ustav

The Narodny Endokrinologicky A Diabetologicky Ustav is actively evaluating new strategies to protect heart health, including studies on atherosclerotic cardiovascular disease, elevated lipoprotein(a), and the prevention of heart failure. Trials aim to reduce major cardiac events and improve kidney outcomes in at‑risk patients.

• Lipoprotein(a) lowering therapies
• Heart failure risk reduction
• Cardiovascular event prevention
• Inflammation and chronic kidney disease interplay

The department conducts 7 clinical trials with 4 investigators in Lubochna, Slovakia, focusing on cardiovascular safety and efficacy.

Research at the institute includes a dedicated program on acromegaly, targeting sustained control of Insulin-like growth factor 1 (IGF‑1) levels. The goal is to maintain hormonal balance while assessing the safety of emerging agents for patients previously treated with somatostatin analogs.

• IGF‑1 level management
• Somatostatin analog optimization
• Growth hormone pathway targeting
• Endocrine treatment safety evaluation

This area contributes to the overall portfolio of 7 trials, supported by a team of 4 investigators.

The department’s metabolic program investigates innovative approaches to treat obesity and type 2 diabetes, with an emphasis on effective weight management and improvement of overall metabolic health. Studies assess novel peptide agents and combination therapies to achieve meaningful weight loss and glycemic control.

• Weight loss interventions
• Diabetes risk reduction
• Metabolic inflammation control
• Novel peptide therapy evaluation

Across all therapeutic areas, the site runs 7 trials under the guidance of 4 investigators in Lubochna, Slovakia.